PMX-53 is a potent, orally bioavailable antagonist of the complement C5a receptor (CD88), inhibiting C5a-mediated neutrophil responses. It also acts as an agonist for Mas-related G-protein coupled receptor X2 (MrgX2). This compound is widely used in research models of inflammation, including in vivo studies of arthritis, psoriasis, and sepsis.